Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Food ...

A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...

New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease controlAXPAXLI ...

Please provide your email address to receive an email when new articles are posted on . In AVONELLE-X, PULSAR and Portal, patients maintained visual acuity and central subfield thickness. No safety ...

New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may ...

Many seniors in their 60s and 70s have likely noticed some vision loss, and this can be a normal part of aging. However, an eye condition known as age-related macular ...

The Agency is now requiring the submission of confirmatory efficacy data to support the application. The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Outlook ...

Please provide your email address to receive an email when new articles are posted on . EYP-1901 and OTX-TKI have shown results similar to aflibercept 2 mg. Gene therapy is another type of treatment ...

Every day tech, like your smartphone or computer, can help manage wet AMD through built-in accessibility features such as voice commands, screen magnification, and high-contrast settings.

This is a quickly progressing field, according to Sarju Patel, MD, attending physician at Retinal Consultants of America. He has high expectations that advances from subtly tinted eyeglass lenses to ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...